Sponsored by:
Produced by:
Introduction
The digital age has ushered in an era where data is the lifeblood of innovation, particularly in the life sciences industry.
As industries globally embrace the transformative power of analytics, the life sciences sector stands at an inflection point. Infinity Research's projection of the global life sciences analytics market growing by an impressive $15.95 billion from 2021-2025, with a compound annual growth rate (CAGR) of 11.83%, is not just a testament to the sector's potential but also a reflection of its urgency.
In response to these emerging challenges, TechPros.io, in collaboration with Genestack, engaged in insightful conversations with industry leaders. Their knowledge and experience offers invaluable perspectives on navigating the evolving data landscape in life sciences. We express our gratitude to Nechama Katan from Pfizer, Amir Emadzadeh from Genentech-Roche, Wolfgang Halter from Merck Gruppe, and Claus A. Andersen for their invaluable contributions. Their insights not only shed light on the current state of the industry but also provide a vision for its data-driven future.
Across these industry leader perspectives, several key themes emerged:
Breaking Down Silos The path to leveraging data and analytics begins with demolishing internal silos that restrict the flow of information. As leaders unanimously agreed, a cohesive, integrated approach is essential for insights.
Enhancing Data Literacy Equipping teams with the skills to locate, understand, and utilise data is crucial. Data science demands specific expertise, requiring investments in specialised talent.
Ensuring Reliability Standardising data for interoperability and implementing robust governance frameworks helps ensure quality, accuracy, and reliability vital for analytics.
Prioritising Flexibility Building agile, cloud-based data architectures allows organisations to scale, keeping pace with needs tomorrow. Fixed legacy systems fall short.
Accelerating Time-to Value Shifting from small proof-of-concepts to high-impact initiatives with proper resources and planning is key to delivering meaningful returns on data science investments.
Amidst these interviews, several key themes emerged, emphasising the challenges and promises of data analytics.
A standout observation was the pressing challenge of data silos and the potential barriers they pose to innovation. Participants also highlighted the critical role of data quality and completeness in driving breakthroughs in life sciences. Another common theme was the transformative potential of data analytics in redefining patient outcomes, fast-tracking drug discovery, and even addressing historical disparities in clinical trials. By ensuring diverse representation in trials, the sector can usher in treatments that are more inclusive and effective across varied demographics.
As Nechama Katan of Pfizer explained, "Innovation from data science simply cannot take place in restrictive environments." To capitalise on this new data-driven landscape, organisations must foster collaboration, enhance data capabilities, and integrate disjointed systems. As Amir Emadzadeh of Genentech-Roche noted, while data's power is widely accepted, few industries actively maximise its potential like pharmaceuticals. The life sciences industry stands at a crossroads, with volumes of data presenting immense potential along with formidable obstacles. Recent polls revealed data silos looming as barriers, with executives rating them 9 out of 10. Meanwhile, 100% agreed dismantling silos promises vast innovations and insights. However, alarmingly low data quality ratings exposed significant gaps jeopardising analytics potential.
Innovation from data science simply cannot take place in restrictive environments.
NECHAMA KATAN
Director, Data Science Insights
The transformative promise of data analytics extends beyond operational efficiency and financial growth. It has the potential to redefine how organisations operate and the pace at which they innovate. However, realising this potential hinges on the robustness and reliability of datasets and the industry's ability to break down data silos. In the subsequent sections of this report, we'll delve deeper into the insights, challenges, and opportunities shared by these thought leaders. Their reflections serve as a beacon for organisations striving to harness the true power of data and analytics in the life sciences domain.
Finally, we would like to express our gratitude to each of the leaders interviewed for this report.
Giving up their time to help provide insight and clarity for the readers of this report is a hugely generous thing to do, for which we are extremely appreciative.
Sponsored by
We are a global player in life-science R&D informatics, providing customers with cutting-edge multi-omics data management and integration software. We develop innovative off-the-shelf and custom solutions for clients in pharma, biotech, agriscience, consumer goods, and research centers. Omics Data Manager (ODM), our flagship product, helps organisations create a FAIR catalogue of multi-omics investigations (studies, samples, omics data), with powerful tools for curating rich and standardised metadata in bulk, as well as optimised RESTful APIs for scalable cross-study, cross-omics integrative search.
Up next: Thoughts from GeneStack
